NKTX
What one share of Nkarta holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies. Our company was founded on the belief that engineered NK cell therapies can transform the lives of patients by offering therapies that are clinically meaningful, broadly accessible and unencumbered by the safety concerns often associated with other cell therapy approaches.
Nkarta’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.58 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$1.27 |
| Cash and investments | $0.35 |
| Book value | $3.46 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.08 | −$14.41 | $1.32 | −$13.88 | — | −$15.92 |
| 2020 | — | −$5.44 | $0.45 | −$3.04 | — | $9.84 |
| 2021 | — | −$2.62 | $0.15 | −$2.22 | — | $7.61 |
| 2022 | — | −$2.61 | $1.08 | −$2.39 | — | $7.62 |
| 2023 | — | −$2.40 | $0.57 | −$2.33 | $0.00 | $5.56 |
| 2024 | $0.00 | −$1.60 | $0.07 | −$1.53 | $0.00 | $5.78 |
| 2025 | $0.00 | −$1.41 | $0.02 | −$1.22 | $0.00 | $4.39 |